---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002996"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:21:31.935237+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neuronetics reports record Q4 2022 revenue $18.2M (+21% YoY); full year $65.2M

## Summary
- Q4 revenue $18.2M, up 21% YoY; US treatment session revenue record $12.5M.
- Full year net loss ($37.2M) or ($1.38) per share vs ($31.2M) or ($1.22) in 2021.
- Cash $70.3M at year-end; guides Q1 2023 revenue $15-16M, FY2023 $66-72M.
- Expanded Greenbrook partnership through 2028; NGS policy allows NPs to order TMS.
- Peer-reviewed publication shows NeuroStar TMS effective for anxious depression.

## SEC filing metadata
- accession: 0001558370-23-002996
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/0001558370-23-002996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/stim-20230307x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002996
- JSON: https://secwatch.observer/filing/0001558370-23-002996.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002996.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported the three months ended December 31, 2022 and the year ended December 31, 2022 results: revenue $65.2 million.
  - Period: the three months ended December 31, 2022 and the year ended December 31, 2022
  - Revenue: $65.2 million
  - Result: reported results
  source text: of $12.5 million in the fourth quarter 2022 ● Increased NeuroStar System revenue 64% over the fourth quarter of 2021 ​ ​ Full Year 2022 Highlights ● Full year 2022 revenue of $65.2 million, representing an 18% increase as compared to full year 2021 ● Full year 2022 U.S. treatment session revenue of $45.1 million ● Full year 2022 U.S. NeuroStar Advanced Therapy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/0001558370-23-002996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.